Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 204

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium

Filter Results:

Show Only CME Accredited Sessions

  • +

    PL01 - Opening Plenary: Access and Disparities

    • 07:00 - 08:00
    • 9/08/2021
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PL01.01 - Introduction and IASLC Award Presentations

      07:00 - 07:30

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      PL01.02 - Disparities in Lung Cancer Care Across the Population

      07:30 - 07:40

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      PL01.03 - Disparities in Lung Cancer Care: The Global Burden

      07:40 - 07:50

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      PL01.04 - Live Discussion with Speakers

      07:50 - 08:00

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

  • +

    PL02 - Plenary 2: Presidential Symposium

    • 06:30 - 08:00
    • 9/09/2021
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
  • +

    PL02A - Plenary 2: Presidential Symposium (Rebroadcast)

    • 14:30 - 16:00
    • 9/09/2021
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
  • +

    JIES01 - Joint IASLC – ESTRO Session: Advances in Radiotherapy for Lung Cancer

    • 07:00 - 08:00
    • 9/10/2021
    • Type: Education Session
    • Track: N.A.
    • +

      JIES01.01 - Introduction

      07:00 - 07:02

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      JIES01.02 - RT in Oligometastatic Disease

      07:02 - 07:12

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      JIES01.03 - Radiomics and Radiotherapy : State of the Art and Future Challenges

      07:12 - 07:22

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      JIES01.04 - Combining Radiotherapy and Immunotherapy

      07:22 - 07:32

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      JIES01.05 - Prophylactic Cranial Irradiation in Lung Cancer : Where We Are?

      07:32 - 07:42

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      JIES01.06 - Live Discussion with Speakers

      07:42 - 08:00

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

  • +

    ES01 - Proactive Tobacco and Cancer Control

    • 07:10 - 07:45
    • 9/10/2021
    • Type: Education Session
    • Track: Risk Reduction and Tobacco Control
    • +

      ES01.01 - Introduction

      07:10 - 07:12

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES01.02 - The Influence of Lung Cancer Provider in Tobacco Control and Policy Advocacy

      07:12 - 07:14

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES01.03 - Setting Clinical Tobacco Cessation Efforts Up for Success

      07:14 - 07:16

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES01.04 - Integration of Cessation Services in Low Dose CT Screening

      07:16 - 07:18

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES01.05 - Examining Health Outcomes in Patients Being Treated for Lung Cancer Who Smoke

      07:18 - 07:20

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES01.06 - Live Discussion with Speakers

      07:20 - 07:45

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

  • +

    ES02 - Multidisciplinary Collaboration in the Treatment of Oligometastatic Disease

    • 08:10 - 08:45
    • 9/10/2021
    • Type: Education Session
    • Track:
    • +

      ES02.01 - Introduction

      08:10 - 08:12

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES02.02 - Overview of Oligometastatic Disease

      08:12 - 08:14

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES02.03 - Surgical Trials in Oligometastatic Disease

      08:14 - 08:16

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES02.04 - Radiation Trials in Oligometastatic Disease

      08:16 - 08:18

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES02.05 - Systemic Thearpy Influenced Trials in Oligometastatic Disease

      08:18 - 08:20

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES02.06 - Uncertainties and Controversies in Oligometastatic Disease

      08:20 - 08:22

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES02.07 - Live Discussion with Speakers

      08:22 - 08:45

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

  • +

    ES03 - Optimizing Survival with Multidisciplinary Collaboration

    • 08:10 - 08:45
    • 9/10/2021
    • Type: Education Session
    • Track:
    • +

      ES03.01 - Introduction

      08:10 - 08:12

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES03.02 - The Effects of Lung Cancer on Patient's Sexual Functioning: Nursing View

      08:12 - 08:14

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES03.03 - Speech Pathology Management in Lung Cancer

      08:14 - 08:16

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES03.04 - Empowering Patients to Make Change: The Use of Motivational Interviewing

      08:16 - 08:18

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES03.05 - Multimodal Intervention (Nutrition, Exercise, Pharmacological) for Cancer Cachexia in Lung Cancer

      08:18 - 08:20

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES03.06 - Enhanced Recovery After Thoracic Surgery

      08:20 - 08:22

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES03.07 - Live Discussion with Speakers

      08:22 - 08:45

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

  • +

    ES04 - Antibody Drug Conjugates: Current Status and Future Perspectives

    • 08:55 - 09:30
    • 9/10/2021
    • Type: Education Session
    • Track:
    • +

      ES04.01 - Introduction

      08:55 - 08:57

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES04.02 - Structure and Mechanism of Antibody Drug Conjugates

      08:57 - 08:59

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES04.03 - Antibody Drug Conjugates About Non-small Cell Lung Cancer

      08:59 - 09:01

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES04.04 - Antibody Drug Conjugates for Other Thoracic Tumor Types

      09:01 - 09:03

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES04.05 - Antibody Drug Conjugates for Combination Therapy

      09:03 - 09:05

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES04.06 - Live Discussion with Speakers

      09:05 - 09:30

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

  • +

    ES05 - A New Era of Treatment and Diagnosis for Mesothelioma and Thymoma

    • 08:55 - 09:30
    • 9/10/2021
    • Type: Education Session
    • Track:
    • +

      ES05.01 - Introduction

      08:55 - 08:57

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES05.02 - Molecular Markers in Mesothelioma

      08:57 - 08:59

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES05.03 - Advances in Immunotherapy in Mesothelioma

      08:59 - 09:01

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES05.04 - CAR T-cell Therapy in Mesothelioma and Thymic Cancer

      09:01 - 09:03

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES05.05 - The Latest Updates in Thymoma

      09:03 - 09:05

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES05.06 - Live Discussion with Speakers

      09:05 - 09:30

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

  • +

    ES06 - Immuno-Biology and Novel Immunotherapeutics in Lung Cancer

    • 09:40 - 10:15
    • 9/10/2021
    • Type: Education Session
    • Track:
    • +

      ES06.01 - Introduction

      09:40 - 09:42

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES06.02 - Task Force in Methodology: Developing New Trials with Immunotherapeutic Agents

      09:42 - 09:44

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES06.03 - Bi-Specific Agents

      09:44 - 09:46

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES06.04 - New Toxicity Management with Bi-Specific Agents and Other New Immunotherapeutic Drugs

      09:46 - 09:48

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES06.05 - Inta-tumoral Immunotherapy

      09:48 - 09:50

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES06.06 - Approach to Chemotherapy for Oncogene-driven Cancers: Known Barriers and Future Promise

      09:50 - 09:52

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.

    • +

      ES06.07 - Live Discussion with Speakers

      09:52 - 10:15

      • Abstract

      The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.